WS
AVNR

Wedbush Securities’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

Wedbush Securities’s Portfolio AVNR Stock Details AVNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-11,013
Closed -$62K – 743
2014
Q2 		$62K Buy
+11,013
New +$50.7K 0.01% 630
2013
Q3 		– Sell
-15,013
Closed -$69K – 622
2013
Q2 		$69K Buy
+15,013
New +$51.6K 0.02% 507

Other funds holding AVNR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
MGM
Miura Global Management New York $25.2M AUM 60.6% 1-Year Est. Return

Wedbush Securities's AVNR Position: Q3 2014 in Review

Wedbush Securities sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q3 2014, closing a stake of 11,013 shares — an estimated $62K sold.

Wedbush Securities first reported a position in AVNR in Q2 2013 and held it in 2 quarters. The position peaked at $69K in Q2 2013. 142 funds tracked by Wall St. Rank hold AVNR as of Q3 2014.

  • Wedbush Securities reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q3 2014 after selling out during the quarter.
  • Wedbush Securities sold 11,013 AVANIR PHARMACEUTICALS, INC CL A shares in Q3 2014, an estimated $62K.
  • Wedbush Securities first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q2 2013 and held it in 2 quarters.
  • Wedbush Securities's AVANIR PHARMACEUTICALS, INC CL A position peaked at $69K in Q2 2013.
  • 142 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q3 2014.

Based on Wedbush Securities's 13F filing for Q3 2014, filed 7 Nov 2014.